长链非编码RNA在前列腺癌早期诊断中的意义

唐勇泉; 张若晨; 梁嘉宇; 王玉杰; 卢一平

doi:10.13201/j.issn.1001-1420.2017.09.017

长链非编码RNA在前列腺癌早期诊断中的意义

- 四川大学华西医院泌尿外科/泌尿外科研究所(成都, 610041)
基金项目:
四川省科学技术厅项目基金（编号2014JY0183）

详细信息

通讯作者: 卢一平,E-mail:yipinglu@163.com

中图分类号: R737.25

收稿日期: 2017-03-27

Significance of long non-coding RNA in early detection of prostate cancer

- Department of Urology/Urological Institute, West China Hospital, Sichuan University, Chengdu, 610041, China

More Information

Corresponding author: LU Yiping, E-mail: yipinglu@163.com

Received Date: 27 March 2017

摘要

摘要: 前列腺癌（PCa）在我国中老年男性人群中的发病率和死亡率都有升高的趋势。目前诊断前列腺癌的无创性检查有血清PSA、直肠前列腺指检、超声及MRI等，这些方法对前列腺癌早期诊断的效能都不高。长链非编码RNA （lnRNA）是基因转录产生的>200bpd的非氨基酸编码mRNA群体，被认为部分参与基因表达调控。有的lnRNA是前列腺癌细胞特异或相对特异的表达产物，被认为是潜在的诊断早期前列腺癌理想的生物标志。本文介绍了目前lnRNA在诊断前列腺癌方面的最新研究进展。
- 长链非编码RNA /
- 前列腺癌 /
- 前列腺癌相关基因3
Abstract: Recently the morbidity and mortality of prostate cancer tended to rise in China.At present some non-invasive examinations including serum PSA, digital rectal examination, ultrasonography and MRI are used for the screening of prostate cancer, but the diagnostic performance was proved to be unideal.Long non-coding RNAs (lnRNAs), >200 bpd, are a series of non-protein-coding transcripts, and they are associated with the regulation of gene expression.Some lnRNAs are specific or relatively specific to prostate cancer, and they are regarded as ideal biomarkers to diagnose prostate cancer.This paper provided an introduction of the most recent reports about lnRNAs.
- long non-coding RNA /
- prostate cancer /
- prostate cancer associated 3

HTML全文

参考文献(32)

[1]	韩苏军, 张思维, 陈万青, 等.中国前列腺癌发病现状和流行趋势分析[J].临床肿瘤学杂志, 2013, 18 (4):330-334.
[2]	韩苏军, 张思维, 陈万青, 等.中国前列腺癌死亡现状及流行趋势分析[J].中华泌尿外科杂志, 2012, 33 (11):836-839.
[3]	van der Cruijsen-Koeter I W, Roobol M J, Wildhagen MF, et al.Tumor characteristics and prognostic factors in two subsequent screening rounds with four-year interval within prostate cancer screening trial, ERSPC Rotterdam[J].Urology, 2006, 68 (3):615-620.
[4]	Aus G, Bergdahl S, Lodding P, et al.Prostate cancer screening decreases the absolute risk of being diagnosed with advanced prostate cancer——results from a prospective, population-based randomized controlled trial[J].Eur Urol, 2007, 51 (3):659-664.
[5]	Carroll P R, Parsons J K, Andriole G, et al.Prostate Cancer Early Detection, Version 2.2015[J].J Natl Compr Canc Netw, 2015, 13 (12):1534-1561.
[6]	Deniz E, Erman B.Long noncoding RNA (lincRNA), a new paradigm in gene expression control[J].Funct Integr Genomics, 2017, 17 (2-3):135-143.
[7]	Bussemakers M J, van Bokhoven A, Verhaegh G W, et al.DD3:a new prostate-specific gene, highly overexpressed in prostate cancer[J].Cancer Res, 1999, 59 (23):5975-5979.
[8]	de Kok J B, Verhaegh G W, Roelofs R W, et al.DD3 (PCA3), a very sensitive and specific marker to detect prostate tumors[J].Cancer Res, 2002, 62 (9):2695-2698.
[9]	Hessels D, Klein Gunnewiek J M, van Oort I, et al.DD3 (PCA3) -based molecular urine analysis for the diagnosis of prostate cancer[J].Eur Urol, 2003, 44 (1):8-15.
[10]	Klecka J, Holubec L, Pesta M, et al.Differential Display Code 3 (DD3/PCA3) in Prostate Cancer Diagnosis[J].Anticancer Res, 2010, 30 (2):665-670.
[11]	Neves A F, Dias-Oliveira J D, Araújo T G, et al.Prostate cancer antigen 3 (PCA3) RNA detection in blood and tissue samples for prostate cancer diagnosis[J].Clin Chem Lab Med, 2013, 51 (4):881-887.
[12]	Tinzl M, Marberger M, Horvath S, et al.DD3PCA3 RNA analysis in urine——a new perspective for detecting prostate cancer[J].Eur Urol, 2004, 46 (2):182-186;discussion 187.
[13]	Ruiz-Aragón J, Márquez-Peláez S.Assessment of the PCA3 test for prostate cancer diagnosis:A systematic review and meta-analysis[J].Actas Urol Esp, 2010, 34 (4):346-355.
[14]	Chevli K K, Duff M, Walter P, et al.Urinary PCA3 as a predictor of prostate cancer in a cohort of 3, 073 men undergoing initial prostate biopsy[J].J Urol, 2014, 191 (6):1743-1748.
[15]	Leyten G, Hessels D, Jannink S A, et al.Prospective Multicentre evaluation of PCA3 and TMPRSS2-ERGgene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer[J].Eur Urol, 2014, 65 (3):534-542.
[16]	Cui Z, Ren S, Lu J, et al.The prostate cancer-up-regulated long noncoding RNA PlncRNA-1 modulates apoptosis and proliferation through reciprocal regulation of androgen receptor[J].Urol Oncol, 2013, 31 (7):1117-1123.
[17]	Crea F, Watahiki A, Quagliata L, et al.Identification of a long non-coding RNA as a novel biomarker and potential therapeutic target for metastatic prostate cancer[J].Oncotarget, 2014, 5 (3):764-774.
[18]	Ji P, Diederichs S, Wang W, et al.MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer[J].Oncogene, 2003, 22 (39):8031-8041.
[19]	Lin R, Maeda S, Liu C, et al.A large noncoding RNA is a marker for murine hepatocellular carcinomas and a spectrum of human carcinomas[J].Oncogene, 2007, 26 (6):851-858.
[20]	Wang F, Ren S, Chen R, et al.Development and prospective multicenter evaluation of the long noncoding RNAMALAT-1as a diagnostic urinary biomarker for prostate cancer[J].Oncotarget, 2014, 5 (22):11091-11102.
[21]	Lee B, Mazar J, Aftab M N, et al.Long noncoding RNAs as putative biomarkers for prostate cancer detection[J].J Mol Diagn, 2014, 16 (6):615-626.
[22]	Bottcher R, Hoogland A M, Dits N, et al.Novel long non-coding RNAs are specific diagnostic and prognostic markers for prostate cancer[J].Oncotarget, 2015, 6 (6):4036-4050.下转第页
[23]	Jiang C Y, Gao Y, Wang X J, et al.Long non-coding RNA lnc-MX1-1is associated with poor clinical features and promotes cellular proliferation and invasiveness in prostate cancer[J].Biochem Biophys Res Commun, 2016, 470 (3):721-727.
[24]	Wan X, Huang W, Yang S, et al.Identification of androgen-responsive lncRNAs as diagnostic and prognostic markers for prostate cancer[J].Oncotarget, 2016, 7 (37):60503-60518.
[25]	Zhang W, Ren S C, Shi X L, et al.A novel urinary long non-coding RNA transcript improves diagnostic accuracy in patients undergoing prostate biopsy[J].Prostate, 2015, 75 (6):653-661.
[26]	Tomlins S A, Rhodes D R, Perner S, et al.Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer[J].Science, 2005, 310 (5748):644-648.
[27]	Hessels D, Smit F P, Verhaegh G W, et al.Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3in urinary sediments may improve diagnosis of prostate cancer[J].Clin Cancer Res, 2007, 13 (17):5103-5108.
[28]	Robert G, Jannink S, Smit F, et al.Rational basis for the combination of PCA3 and TMPRSS2:ERG gene fusion for prostate cancer diagnosis[J].Prostate, 2013, 73 (2):113-120.
[29]	Mearini E, Antognelli C, Del Buono C, et al.The combination of urine DD3 (PCA3) mRNA and PSA mRNA as molecular markers of prostate cancer[J].Biomarkers, 2009, 14 (4), 235-243.
[30]	Nygrd Y, Haukaas S A, Waage J E, et al.Combination of real-time elastography and urine prostate cancer gene3 (PCA3) detects more than 97%of significant prostate cancers[J].Scand J Urol, 2013, 47 (3):211-216.
[31]	PerdonàS, Bruzzese D, Ferro M, et al.Prostate health index (phi) and prostate cancer antigen 3 (PCA3) significantly improve diagnostic accuracy in patients undergoing prostate biopsy[J].Prostate, 2013, 73 (3):227-235.
[32]	Scattoni V, Lazzeri M, Lughezzani G, et al.Head-toHead Comparison of Prostate Health Index and Urinary PCA3 for Predicting Cancer at Initial or Repeat Biopsy[J].J Urol, 2013, 190 (2):496-501.